1990505-73-1

Upstream product

• 113516-71-5 (1R,2S)-2-(4-fluorophenyl)cyclopropan-1-amine 
• 210422-66-5 4-fluorobenzaldehyde p-toluenesulfonylhydrazone 
• 459-57-4 4-fluorobenzaldehyde 
• 107633-40-9 4-fluorophenyl benzaldehyde-tosylhydrazone sodium salt 
• 161711-27-9 (1R,2R)-2-(4-fluorophenyl)cyclopropanecarboxylic acid 
• 405-99-2 para-fluorostyrene 
• 1314323-96-0 (1R,2S)-tert-butyl 2-(4-fluorophenyl)cyclopropylcarbamate 
• 96426-60-7 methyl (2E)-3-(4-fluorophenyl)-2-propenoate 
• 352-34-1 4-fluoro-1-iodobenzene 
• 515179-19-8 (±)-trans-2-(4-fluorophenyl)cyclopropane-1-carboxylic acid 
• 879324-65-9 [2-(4-fluoro-phenyl)-cyclopropyl]-carbamic acid tert-butyl ester 
• 893751-08-1 trans-methyl 2-(4-fluorophenyl)cyclopropanecarboxylate 

Relevant academic research and scientific papers

CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS

The present disclosure describes novel compounds of the general Formula (I), their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds can inhibit both LSD and HDAC and are useful as therpeautic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, parkinson's disease and the like.

C-H activation enables a rapid structure-activity relationship study of arylcyclopropyl amines for potent and selective LSD1 inhibitors

We describe the structure-activity relationship of various arylcyclopropylamines (ACPAs), which are potent LSD1 inhibitors. More than 45 ACPAs were synthesized rapidly by an unconventional method that we have recently developed, consisting of a C-H borylation and cross-coupling sequence starting from cyclopropylamine. We also generated NCD38 derivatives, which are known as LSD1 selective inhibitors, and discovered a more effective inhibitor compared to the original NCD38.

NOVEL COMPOUNDS

Compounds of the formula (I), in which the substituents are as defined in claim 1, are suitable for use as nematicides.

NOVEL COMPOUNDS

Compounds of the formula (I), in which the substituents are as defined in claim 1, are suitable for use as nematicides.

Enantioselective synthesis of tranylcypromine analogues as lysine demethylase (LSD1) inhibitors

Asymmetric cyclopropanation of styrenes by tert-butyl diazoacetate followed by ester hydrolysis and Curtius rearrangement gave a series of tranylcypromine analogues as single enantiomers. The o,- m- and p-bromo analogues were all more active than tranylcypromine in a LSD1 enzyme assay. The m- and p-bromo analogues were micromolar growth inhibitors of the LNCaP prostate cancer cell line as were the corresponding biphenyl analogues prepared from the bromide by Suzuki crosscoupling.

Novel trans-2-aryl-cyclopropylamine analogues as potent and selective dipeptidyl peptidase IV inhibitors

A series of trans-2-aryl-cyclopropylamine derived compounds were synthesized and evaluated their biological activities against DPP-IV. The structure-activity relationships (SAR) led to the discovery of novel series of DPP-IV inhibitors, having IC50 values of 100 nM with excellent selectivity over the closely related enzymes, DPP8, DPP-II and FAP. The studies identified a potent and selective DPP-IV inhibitor 24b, which exhibited the ability to both significantly inhibit plasma DPP-IV activity in rats and improve glucose tolerance in lean mice and diet induced obese mice.

Novel selective inhibitors of neutral endopeptidase for the treatment of female sexual arousal disorder

A series of substituted glutaramides were synthesised using Candoxatrilat 1 as a lead and evaluated for potency against neutral endopeptidase (NEP) as a potential treatment for female sexual arousal disorder (FSAD). In this paper, we describe studies in which we were able to increase NEP activity substantially over the levels reported for previous compounds from this programme by appropriate substitution in both the P1′ and P2′ regions. Optimisation led to the 4-chlorophenpropylamide S-30 which was selected as a candidate for further study.

Thiazolinone 4-monosubstituted quinolines

Thiazolinone monosubstituted quinoline derivatives where the quinoline ring is mono-substituted at the 4 positions which derivatives demonstrates CDK1 antiproliferative activity and are useful as anti-cancer agents.

trans-2-Aryl-N,N-dipropylcyclopropylamines: Synthesis and interactions with 5-HT(1A) receptors

Twelve N,N-dipropyl-substituted derivatives of trans-2- arylcyclopropylamine have been prepared and assayed for their ability to displace [3H]-8-OH-DPAT from rat brain 5-HT(1A) receptors. The new derivatives include phenyl (7a), bromo- (7b) and fluorophenyl (7c-e), 2- methoxy-5-fluorophenyl (7h), and 2-hydroxy-5-fluorophenyl (71) as well as trifluoromethylphenyl (7f) and 2,3-dichlorophenyl (7g) analogues. In the present series of compounds, electron-withdrawing substituents in the phenyl ring appear to decrease the affinity for 5-HT(1A) receptors. In contrast, electron-rich aryl groups, such as 2- or 3-thienyl (7j and 7k, respectively), provide compounds with high affinity. The additional bulk produced by the aromatic moiety in the 2-benzothienyl derivative 7i appears to be detrimental to 5-HT(1A) receptor affinity. The racemic mixtures of the interesting 7j and 7l were resolved into the enantiomers; 7j and 7l exhibited a high enantiomeric 5-HT(1A) receptor affinity ratio (75-fold and 100-fold, respectively). The enantiomers of 7j and 7l were evaluated in vivo by use of biochemical and behavioral tests in rats. Compound (1R,2R)-7j behaved as a partial agonist whereas (1R,2S)-7l appeared as an efficacious 5-HT(1A) receptor agonist, stimulating both autoreceptors and postsynaptic receptors.